Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
70+ CXOs from leading healthcare institutions across India attended the confluence at Mumbai
States advised to undertake mock drills to ensure operational readiness of Hospital Infrastructure including Oxygen Cylinders, PSA plants, ventilators and human resources
Department of Biotechnology is going to play an important part in the integrated holistic healthcare approach against elimination of Tuberculosis
The company is addressing these observations
India has a pivotal role in eliminating TB
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
Essex enriches and complements Emmes’ services
Subscribe To Our Newsletter & Stay Updated
